Option chain shows key data for Valeo's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Valeo.

Valeo (OTC:VLEEY) Stock, Option Chain

Valeo

Based in France, Valeo is an automotive parts supplier that operates through four business segments, including powertrain systems (PTS, 31% of 2022 revenue), thermal systems (THS, 22%), comfort and driving assistance systems (CDA, 22%), and visibility systems (VIS, 25%). As of 2022, Valeo generated 84% of its revenue through original equipment sales and 11% of revenue through aftermarket parts. The firm's five largest automaker customers accounted for 53% of 2022 revenue. Europe is Valeo's largest geographic market at 45% of 2022 revenue, followed by Asia at 33%, and Americas at 22%.

News

Intraday Update

Markets

Movers

Trading Ideas

AAEEF

AAVMY

ABEV

ABGSF

ABMD

ABTX

ACCFF

ACCYY

ACHV

ACNB

ACRFF

ACRGF

ACSAY

ACST

ACTG

ADMA

ADTN

ADVZF

AERI

AFLYY

AGCO

AGEEF

AGESY

AGLXY

AHFD

AHKSY

AHOTF

AICAF

AINV

AIPUY

AIRG

AIRYY

AISSF

AKO-A

AKZOY

ALDX

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

ALEX

Allianz Ag Muenchen Namen-Akt Vinkuliert Shares

ALIZF

ALLY

ALOT

ALSN

ALTM

ALXEF

ALXN

AMCR

AMHPF

AMKBF

AMKBY

AMNB

AMPH

AMRN

AMSLF

ANAT

ANGO

ANIP

Australia and New Zealand Banking Group Limited

ANZBY

ANZFF

APELY

APEX

APHA

APTS

ARCB

ARCC

ARGGY

ARGO

ARLP

ARNA

ARNGF

AROC

ARREF

ARRRF

Stocks That Hit 52-Week Lows On Friday

ABIO

ABVC

ACIW

ACOR

ACRX

ADHC

ADMP

AEGOF

AFRAF

AIBGY

AKRX

ALMFF

AMADY

AMCX

AMNP

AMRH

AMRQQ

AMTX

ANCN

ANZLY

APLE

AQARF

ARCH

ARTL

ASNA

ASTVF

ATRA

ATRI

ATROB

ATSG

ATUSF

AUTL

Stocks That Hit 52-Week Lows On Thursday

AGBA

ALLE

ALNY

AMED

AMGN

AMWD

ANSS

APPF

AQUA

ARVN

ARWR

ATKR

ATRS

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

BALMF

BGNE

BNTX

BWLLY

CACI

CARCY

CATM

CATN

CBNK

CBOE

CBSH

CMPGY

CNMD

CNNE

CNSWF

CTXS

CVNA

DAVA

DEWY

DKILY

DOCU

DRGDF

DRNA

DRTGF

DSGX

DXCM

EUENF

EVER

EXPGF

EXPGY

FCAP

FIVN

FJTSY

FLOW

GAIN

GMAB

GMRE

GWRE

HALO

HCCI

HCHMY

HLMAF

HNGR

HUBG

HWDJY

HZNP

IKTSY

INCY

INFO

INSW

KDSKF

KMDA

KPTI

KRYS

KXSCF

LAWS

Stocks That Hit 52-Week Highs On Monday

Valeo SA

&nbsp;
<h2>Upgrades</h2>
<ul>
<li>According to Roth Capital, the prior rating for Seelos Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) was changed from Neutral to Buy. For the second quarter, Seelos Therapeutics had an EPS of $0.08, compared to year-ago quarter EPS of $0.08. The current stock performance of Seelos Therapeutics shows a 52-week-high of $6.60 and a 52-week-low of $0.56. Moreover, at the end of the last trading period, the closing price was at $2.09.</li>
<li>For Yandex NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YNDX#NASDAQ">YNDX</a>), UBS upgraded the previous rating of Neutral to Buy. For the second quarter, Yandex had an EPS of $0.04, compared to year-ago quarter EPS of $0.08. The stock has a 52-week-high of $82.62 and a 52-week-low of $55.62. At the end of the last trading period, Yandex closed at $80.20.</li>
<li>SVB Leerink upgraded the previous rating for Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) from Market Perform to Outperform. Sanofi earned $1.66 in the second quarter, compared to $1.41 in the year-ago quarter. At the moment, the stock has a 52-week-high of $54.26 and a 52-week-low of $44.76. Sanofi closed at $47.94 at the end of the last trading period.</li>
<li>According to JMP Securities, the prior rating for Viant Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) was changed from Market Perform to Market Outperform. Interestingly, in the second quarter, Viant Technology&#39;s EPS was $0.06. The current stock performance of Viant Technology shows a 52-week-high of $69.16 and a 52-week-low of $11.49. Moreover, at the end of the last trading period, the closing price was at $12.69.</li>
<li>JMP Securities upgraded the previous rating for Box Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) from Market Perform to Market Outperform. Box earned $0.21 in the second quarter, compared to $0.18 in the year-ago quarter. The current stock performance of Box shows a 52-week-high of $27.41 and a 52-week-low of $15.07. Moreover, at the end of the last trading period, the closing price was at $25.24.</li>
<li>Atlantic Equities upgraded the previous rating for Bath &amp; Body Works Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) from Neutral to Overweight. In the second quarter, Bath &amp; Body Works earned $1.34.Bath &amp; Body Works closed at $67.39 at the end of the last trading period.</li>
<li>For Icon PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>), JP Morgan upgraded the previous rating of Neutral to Overweight. For the second quarter, Icon had an EPS of $2.12, compared to year-ago quarter EPS of $1.20. At the moment, the stock has a 52-week-high of $284.20 and a 52-week-low of $168.76. Icon closed at $283.04 at the end of the last trading period.</li>
<li>For National Instruments Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATI#NASDAQ">NATI</a>), Goldman Sachs upgraded the previous rating of Neutral to Buy. For the second quarter, National Instruments had an EPS of $0.35, compared to year-ago quarter EPS of $0.26. At the moment, the stock has a 52-week-high of $47.40 and a 52-week-low of $30.42. National Instruments closed at $41.16 at the end of the last trading period.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
&nbsp;
<h2>Downgrades</h2>
<ul>
<li>According to Credit Suisse, the prior rating for Altice USA Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATUS#NYSE">ATUS</a>) was changed from Outperform to Neutral. In the second quarter, Altice USA showed an EPS of $0.51, compared to $0.19 from the year-ago quarter. At the moment, the stock has a 52-week-high of $38.30 and a 52-week-low of $19.74. Altice USA closed at $20.58 at the end of the last trading period.</li>
<li>B of A Securities downgraded the previous rating for Hyatt Hotels Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) from Neutral to Underperform. Hyatt Hotels earned $1.15 in the second quarter, compared to $1.80 in the year-ago quarter. The current stock performance of Hyatt Hotels shows a 52-week-high of $92.22 and a 52-week-low of $51.21. Moreover, at the end of the last trading period, the closing price was at $79.76.</li>
<li>For American Water Works Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWK#NYSE">AWK</a>), B of A Securities downgraded the previous rating of Neutral to Underperform. American Water Works Co earned $1.14 in the second quarter, compared to $0.97 in the year-ago quarter. The current stock performance of American Water Works Co shows a 52-week-high of $189.35 and a 52-week-low of $131.01. Moreover, at the end of the last trading period, the closing price was at $176.79.</li>
<li>JP Morgan downgraded the previous rating for Talis Biomedical Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLIS#NASDAQ">TLIS</a>) from Neutral to Underweight. Interestingly, in the second quarter, Talis Biomedical&#39;s EPS was $2.51. The stock has a 52-week-high of $33.90 and a 52-week-low of $6.81. At the end of the last trading period, Talis Biomedical closed at $7.04.</li>
<li>For Zymergen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZY#NASDAQ">ZY</a>), JP Morgan downgraded the previous rating of Neutral to Underweight. Interestingly, in the second quarter, Zymergen&#39;s EPS was $1.30. The current stock performance of Zymergen shows a 52-week-high of $52.00 and a 52-week-low of $7.85. Moreover, at the end of the last trading period, the closing price was at $13.40.</li>
<li>According to Goldman Sachs, the prior rating for Lordstown Motors Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIDE#NASDAQ">RIDE</a>) was changed from Neutral to Sell. In the second quarter, Lordstown Motors showed an EPS of $0.61, compared to $0.11 from the year-ago quarter. The stock has a 52-week-high of $31.57 and a 52-week-low of $4.77. At the end of the last trading period, Lordstown Motors closed at $7.57.</li>
<li>Raymond James downgraded the previous rating for Altice USA Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATUS#NYSE">ATUS</a>) from Outperform to Market Perform. For the second quarter, Altice USA had an EPS of $0.51, compared to year-ago quarter EPS of $0.19. At the moment, the stock has a 52-week-high of $38.30 and a 52-week-low of $19.74. Altice USA closed at $20.58 at the end of the last trading period.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
&nbsp;
<h2>Initiations</h2>
<ul>
<li>With a Hold rating, Vertical Research initiated coverage on Ecolab Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>). The price target seems to have been set at $189.00 for Ecolab. In the second quarter, Ecolab showed an EPS of $1.22, compared to $0.65 from the year-ago quarter. The current stock performance of Ecolab shows a 52-week-high of $231.25 and a 52-week-low of $181.25. Moreover, at the end of the last trading period, the closing price was at $223.77.</li>
<li>With a Buy rating, Craig-Hallum initiated coverage on dMY Technology Group Inc IV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DMYQ#NYSE">DMYQ</a>). The price target seems to have been set at $15.00 for dMY Technology Group Inc. The current stock performance of dMY Technology Group Inc shows a 52-week-high of $10.48 and a 52-week-low of $9.57. Moreover, at the end of the last trading period, the closing price was at $9.95.</li>
<li>With a Buy rating, Maxim Group initiated coverage on SPI Energy Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPI#NASDAQ">SPI</a>). The price target seems to have been set at $12.00 for SPI Energy. At the moment, the stock has a 52-week-high of $28.71 and a 52-week-low of $4.59. SPI Energy closed at $5.36 at the end of the last trading period.</li>
<li>With a Buy rating, Canaccord Genuity initiated coverage on Pacific Biosciences of California Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>). The price target seems to have been set at $45.00 for Pacific Biosciences. In the second quarter, Pacific Biosciences showed an EPS of $0.21, compared to $0.15 from the year-ago quarter. The stock has a 52-week-high of $53.69 and a 52-week-low of $8.05. At the end of the last trading period, Pacific Biosciences closed at $25.58.</li>
<li>Cantor Fitzgerald initiated coverage on Sierra Oncology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRA#NASDAQ">SRRA</a>) with an Overweight rating. The price target for Sierra Oncology is set to $33.00. For the second quarter, Sierra Oncology had an EPS of $1.41, compared to year-ago quarter EPS of $1.58. The current stock performance of Sierra Oncology shows a 52-week-high of $23.85 and a 52-week-low of $10.02. Moreover, at the end of the last trading period, the closing price was at $22.45.</li>
<li>With an Outperform rating, SVB Leerink initiated coverage on UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>). The price target seems to have been set at $480.00 for UnitedHealth Group. In the second quarter, UnitedHealth Group showed an EPS of $4.70, compared to $7.12 from the year-ago quarter. The stock has a 52-week-high of $431.36 and a 52-week-low of $289.64. At the end of the last trading period, UnitedHealth Group closed at $407.08.</li>
<li>SVB Leerink initiated coverage on Mednax Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) with a Market Perform rating. The price target for Mednax is set to $29.00. Mednax earned $0.41 in the second quarter, compared to $0.32 in the year-ago quarter. The current stock performance of Mednax shows a 52-week-high of $35.67 and a 52-week-low of $12.47. Moreover, at the end of the last trading period, the closing price was at $28.85.</li>
<li>With a Market Perform rating, Keefe, Bruyette &amp; Woods initiated coverage on Jackson Financial Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JXN#NYSE">JXN</a>). The price target seems to have been set at $30.00 for Jackson Financial. In the second quarter, Jackson Financial earned $6.74.&nbsp;&nbsp;Jackson Financial closed at $27.90 at the end of the last trading period.</li>
<li>SVB Leerink initiated coverage on AdaptHealth Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) with an Outperform rating. The price target for AdaptHealth is set to $30.00. For the second quarter, AdaptHealth had an EPS of $0.17, compared to year-ago quarter EPS of $0.08. At the moment, the stock has a 52-week-high of $41.58 and a 52-week-low of $19.17. AdaptHealth closed at $23.00 at the end of the last trading period.</li>
<li>SVB Leerink initiated coverage on Acadia Healthcare Co Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with an Outperform rating. The price target for Acadia Healthcare Co is set to $85.00. In the second quarter, Acadia Healthcare Co showed an EPS of $0.71, compared to $0.54 from the year-ago quarter. The current stock performance of Acadia Healthcare Co shows a 52-week-high of $68.65 and a 52-week-low of $27.07. Moreover, at the end of the last trading period, the closing price was at $65.15.</li>
<li>SVB Leerink initiated coverage on Tenet Healthcare Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Market Perform rating. The price target for Tenet Healthcare is set to $80.00. For the second quarter, Tenet Healthcare had an EPS of $1.59, compared to year-ago quarter EPS of $1.26. At the moment, the stock has a 52-week-high of $76.16 and a 52-week-low of $21.34. Tenet Healthcare closed at $71.39 at the end of the last trading period.</li>
<li>SVB Leerink initiated coverage on Humana Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with an Outperform rating. The price target for Humana is set to $494.00. Humana earned $6.89 in the second quarter, compared to $12.56 in the year-ago quarter. The current stock performance of Humana shows a 52-week-high of $475.44 and a 52-week-low of $370.22. Moreover, at the end of the last trading period, the closing price was at $398.91.</li>
<li>SVB Leerink initiated coverage on Cigna Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Market Perform rating. The price target for Cigna is set to $220.00. For the second quarter, Cigna had an EPS of $5.24, compared to year-ago quarter EPS of $5.81. The stock has a 52-week-high of $272.81 and a 52-week-low of $158.84. At the end of the last trading period, Cigna closed at $203.89.</li>
<li>SVB Leerink initiated coverage on Amedisys Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) with a Market Perform rating. The price target for Amedisys is set to $170.00. For the second quarter, Amedisys had an EPS of $1.69, compared to year-ago quarter EPS of $1.34. The stock has a 52-week-high of $325.12 and a 52-week-low of $154.52. At the end of the last trading period, Amedisys closed at $155.35.</li>
<li>SVB Leerink initiated coverage on HCA Healthcare Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with an Outperform rating. The price target for HCA Healthcare is set to $320.00. In the second quarter, HCA Healthcare showed an EPS of $4.37, compared to $3.23 from the year-ago quarter. The stock has a 52-week-high of $263.92 and a 52-week-low of $114.38. At the end of the last trading period, HCA Healthcare closed at $256.33.</li>
<li>With a Market Perform rating, SVB Leerink initiated coverage on Anthem Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANTM#NYSE">ANTM</a>). The price target seems to have been set at $403.00 for Anthem. For the second quarter, Anthem had an EPS of $7.03, compared to year-ago quarter EPS of $9.20. The current stock performance of Anthem shows a 52-week-high of $406.00 and a 52-week-low of $244.10. Moreover, at the end of the last trading period, the closing price was at $381.33.</li>
<li>With an Outperform rating, SVB Leerink initiated coverage on Agilon Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>). The price target seems to have been set at $37.00 for Agilon Health. Agilon Health earned $0.79 in the second quarter. At the moment, the stock has a 52-week-high of $44.83 and a 52-week-low of $26.50. Agilon Health closed at $28.10 at the end of the last trading period.</li>
<li>JP Morgan initiated coverage on Omeros Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Neutral rating. The price target for Omeros is set to $15.00. Omeros earned $0.46 in the second quarter, compared to $0.61 in the year-ago quarter. The current stock performance of Omeros shows a 52-week-high of $23.85 and a 52-week-low of $9.25. Moreover, at the end of the last trading period, the closing price was at $15.88.</li>
<li>With a Buy rating, Jefferies initiated coverage on Kinnate Biopharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNTE#NASDAQ">KNTE</a>). The price target seems to have been set at $46.00 for Kinnate Biopharma. Kinnate Biopharma earned $0.49 in the second quarter, compared to $2.05 in the year-ago quarter. The current stock performance of Kinnate Biopharma shows a 52-week-high of $48.75 and a 52-week-low of $17.58. Moreover, at the end of the last trading period, the closing price was at $22.67.</li>
<li>With a Neutral rating, JP Morgan initiated coverage on Airbnb Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>). The price target seems to have been set at $170.00 for Airbnb. For the second quarter, Airbnb had an EPS of $0.11, compared to year-ago quarter EPS of $1.30. The current stock performance of Airbnb shows a 52-week-high of $219.94 and a 52-week-low of $121.50. Moreover, at the end of the last trading period, the closing price was at $175.88.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Comments

Valeo

Valeo (VLEEY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga